Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir/Ritonavir vs Comparator PI/Ritonavir in Experienced HIV Patients
NCT00054717Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2003
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of tipranavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Treatment Response at 48 weeks and Time to Treatment Failure at 48 weeks. Started Jan 2003; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00054717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054717.